Foundation Medicine Inc. (FMI) COO Steven J. Kafka Sells 6,273 Shares of Stock
Foundation Medicine Inc. (NASDAQ:FMI) COO Steven J. Kafka sold 6,273 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $23.01, for a total value of $144,341.73. Following the transaction, the chief operating officer now directly owns 103,009 shares in the company, valued at approximately $2,370,237.09. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Steven J. Kafka also recently made the following trade(s):
- On Tuesday, October 4th, Steven J. Kafka sold 2,135 shares of Foundation Medicine stock. The stock was sold at an average price of $23.62, for a total value of $50,428.70.
Foundation Medicine Inc. (NASDAQ:FMI) traded up 1.634% during mid-day trading on Wednesday, hitting $23.325. The company’s stock had a trading volume of 39,660 shares. The stock’s market cap is $817.73 million. Foundation Medicine Inc. has a 52-week low of $13.34 and a 52-week high of $25.31. The company’s 50 day moving average is $22.46 and its 200-day moving average is $21.53.
Foundation Medicine (NASDAQ:FMI) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by $0.02. Foundation Medicine had a negative return on equity of 42.21% and a negative net margin of 84.67%. The firm earned $29.43 million during the quarter, compared to the consensus estimate of $28.70 million. During the same period in the previous year, the firm earned ($0.60) EPS. The business’s revenue was up 15.9% on a year-over-year basis. On average, equities analysts predict that Foundation Medicine Inc. will post ($3.21) EPS for the current fiscal year.
Several hedge funds have recently modified their holdings of FMI. Barclays PLC raised its stake in shares of Foundation Medicine by 7,965.2% in the first quarter. Barclays PLC now owns 37,503 shares of the company’s stock valued at $675,000 after buying an additional 37,038 shares during the last quarter. Chevy Chase Trust Holdings Inc. raised its stake in Foundation Medicine by 21.4% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 729,310 shares of the company’s stock valued at $13,609,000 after buying an additional 128,770 shares in the last quarter. Private Capital Advisors Inc. bought a new stake in Foundation Medicine during the second quarter valued at about $328,000. Strs Ohio raised its stake in Foundation Medicine by 262.5% in the second quarter. Strs Ohio now owns 14,500 shares of the company’s stock valued at $270,000 after buying an additional 10,500 shares in the last quarter. Finally, Whittier Trust Co. raised its stake in Foundation Medicine by 1.2% in the second quarter. Whittier Trust Co. now owns 39,835 shares of the company’s stock valued at $743,000 after buying an additional 483 shares in the last quarter. 31.11% of the stock is owned by institutional investors.
A number of analysts recently issued reports on the company. Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Friday, September 9th. Benchmark Co. cut Foundation Medicine from a “buy” rating to a “hold” rating in a report on Thursday, November 3rd. BTIG Research reissued a “hold” rating on shares of Foundation Medicine in a report on Thursday, August 4th. Janney Montgomery Scott cut Foundation Medicine from a “neutral” rating to a “sell” rating and set a $15.00 price objective on the stock. in a report on Wednesday, August 3rd. Finally, JPMorgan Chase & Co. reissued a “hold” rating and set a $25.00 price objective on shares of Foundation Medicine in a report on Wednesday, August 3rd. Two research analysts have rated the stock with a sell rating and five have issued a hold rating to the company. The stock presently has an average rating of “Hold” and an average price target of $19.20.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. Its products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies.
Receive News & Stock Ratings for Foundation Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc. and related stocks with our FREE daily email newsletter.